Introduction
It is well recognized that increasing the multiplicity of infection of viruses and bacteria requires increasing dose levels of antibiotics and antiviral drugs to achieve therapeutic or prophylactic effects. This has been observed in cell cultures (Harmenberg et al., 1980) , in experimental infections in animals (Lang et aI., 1970; Grunert and Hoffmann, 1977; Field et al., 1979; Schinazi, 1987; Zak and O'Reilly, 1990) and in challenge experiments in humans (Jackson, 1975) . Thus it is important to determine the influence of virus dose on treatment efficacy in model systems for human infections.
Experimental infection of cynomolgus monkeys with simian immunodeficiency virus (SIV) using SIV sM isolated from sooty mangabeys (Fultz et al., 1986 ) represents a treatment model with a high similarity to the human immunodeficiency virus (HIV) infection and the development of the acquired immunodeficiency syndrome (AIDS) in humans (McClure et al., 1989; Putkonen et al., 1989 Putkonen et al., , 1990 Lundgren et al., 1990 Lundgren et al., , 1991 . This similarity includes genome sequences and functions as well as viral replication and pathogeneses. However, the time from infection to death is shorter in monkeys, than in humans which correlates to the expected lifetime of these species.
3'-Fluorothymidine (FL1) is a potent inhibitor of HIV and SIV multiplication (Herdewijn et al., 1987; Balzarini et al., 1988; Hartmann etal., 1988; Matthes etal., 1988; Bazin et al., 1989; Koshida et al., 1989; Tsai et aI., 1990; Lundgren et al., 1991) and has recently been shown to delay the appearance of viral antigen in cynomolgus monkeys infected with SIVSM (Lundgren et al., 1991) . FLT is structurally similar to 3'-azidothymidine and it acts in the same way by being phosphorylated by cellular kinases to FLT triphosphate which is an effective inhibitor of reverse transcriptase (Matthes et al., 1988) .
We have used the SIV sM infection model in cynomolgus monkeys to study how the infectious dose of SIV s M influences antigenaemia in the acute infection and the response to treatment with FLT. The choice of FLTwas based on the fact that it was found to be 10 times more active than 3'-azidothymidine in this SIV monkey model (Lundgren et aI., 1991) . The influence of virus dose had earlier not been determined and was found to be of fundamental importance in the design of studies evaluating anti-HIV drugs in SIV-infected monkeys.
Results

Untreated monkeys
The characteristics of the two SIV s M pools used for inoculation are given in Table 1 . SIV s M pool I was diluted to give 10-100 MID so rnl"" and pool II was diluted to give 2-10,10-50, and 500-2500 MID so mr'. The appearances of p24/26 SIV sM antigen in untreated monkeys given 1ml i.v, each of four different SIV sM dilutions are shown in 0-0 SIV sM pool II 2-10 MID so (n = 8).
30 Table 1 . Characteristics of SIVSMpools.
Discussion
The influence of the infectious dose on the therapeutic effects of drugs has not earlier been reported for monkeys infected with SIV. The present results show that both the time for appearance of SIV sM p24/26 antigen and the effect of treatment with FLT are dependent on the infectious dose.
There was a good correlation between TCID so and MID so for the two pools of SIV sM studied (Table 1) . The MID so values were about ten-fold higher than the TCID so values. This is possibly somewhat higher than was reported by McClure et at. (1990) , but small numbers of animals and different titration methods could account for the difference. The RT activity in the SIVSM pools did not correspond to the TCID so values indicating different proportions of infectious and non-infectious particles in the two pools and/or the presence of different amounts of contaminating nucieases (Buckheit and Swanstrom 1991) .
' The treatment results in monkeys correspond to earlier studies in cell cultures where the inhibition of SIV SM by FLT and 3'-azidothymidine (AZT) was dependent on the multiplicity of infection (Lundgren et al., 1991) . FLT treatment was earlier shown to delay the appearance of SIV sM p24/26 antigen in monkeys when an infectious dose of 10-100 MID so was used, but not to prevent infection (Lundgren et al., 1991) . In the present study 3 of 4 animals TCID so mr ' RT activity cpm m!' 2 X 10 5 3.4 X 10 5 10 3-104 2.5 X 10 2 5 x 10 4-2.5 X 10 5 3.4 X 10 3
SIV-pool
MIDso rnr '
FLT-treated monkeys
In monkeys treated with 3 x 5mg kg-1 day-1 of FLT, the time for appearance of viral antigen was dependent on the virus dose given ( Fig. 2a-d ). Viral antigen appeared first in the group which received the highest virus dose, parallelto the findings in the untreated control groups (Fig. 1) . No significant effect of treatment with FLT was seen in monkeys inoculated with 500-2500 MID so ( Fig. 2a ) but there was a trend to a later appearance. However, treatment with FLT caused a significant delay in the time for appearance of SIV sM p24/26 antigen compared to the controls, when the monkeys were inoculated with less than 100 MID so (Fig. 2b,c,d) . One FLT-treated monkey given 10-50 MID so of SIV sM and three treated monkeys given 2-10 MID so of SIV sM lacked measurable viral antigen, which is reflected in low average antigen curves ( Fig.2c,d ). These animals were followed for up to 6 months and three animals remained SIV-uninfected as determined by lack of antibodies and negative virus isolation. One of the antigen negative monkeys given 2-10 MID so of SIV SM seroconverted and became SIV antibody and virus isolation positive on day 60.
In the statistical calculations in Fig. 2c,d , animals not showing any p24/26 antigen were attributed to the same time point for antigen appearance as the latest seen in the treated animals in each experiment.
The appearance of viral antigen was delayed when the virus dose was decreased. The time for appearance of p24/26 antigen was statistically delayed when the animals given 2-10, 10-50, and 10-100 MID so were compared to those given 500-2500 MID so . There was no difference in the amount of p24/26 antigen appearing in the control monkeys after inoculation with the different doses of SIV sM (Fig. 1) . given the lowest dose of SIV sM (2-10 MID so ) lacked detectable antigen and two of these monkeys were prevented from infection as judged by failure to detect virus by isolation and no seroconversion at up to 180 days. The difference in time for antigen appearance after FLT-treatment in Fig. 2b ,c is probably due to the fact that two different pools of SIV sM were used and the precise titres are not known, only the intervals which were 10-100 (Pool I) and 10-50 (Pool II). Thus, the actual difference between the virus doses could be large. In 'all other comparisons dilutions of pool II were used which gave exact relative values.
Previous experiments included, the lowest dose of virus has given an increase in p24/26 viral antigen in all 8 control animals and therefore, it is possible that FLT, given prophylactically, can prevent infection at a low virus dose, These results resemble those in monkeys vaccinated against SIV where a low challenge dose of SIV resulted in protection of some animals while a high challenge dose infected all monkeys (Gardner and Luciw, 1989), McClure et al. (1990) reported that high doses (100mg kg-1 day" for 2 weeks) of AlT, 3'-azidodeoxyuridine (AzddU), 2',3'-dideoxythymidine (d4T) and FLT given prophylactically failed to prevent SIV SM infection of Rhesus macaques with the exception of one monkey in the FLT treatment group. The time for appearance of viral antigen was not reported, but the infectious dose was high, 150 TCID so per monkey, and, according to the present results, this could limit the possibility of observing a delay in appearance of virus or a prevention of infection.
In contrast to the influence of infectious dose on time to viral antigen appearance there was no effect on the amount of SIV SM p24/26 antigen produced (Fig. 1) . This corresponds to the results of Daniel et al. (1987) who did not observe any effect on antibody titre or clinical outcome after using SIV at different infectious doses in macaques.
The use of doses lower than 2-10 MID so might give better experimental effects with anti-HIV drugs, However, the limited number of monkeys that it is possible to include in each treatment group counteracts such a design and could result in uninfected control monkeys and thus rapidly decrease the possibility of reaching statistical significance of any effect.
The dependence on infectious dose for treatment efficacy could also be of clinical relevance. Increasing levels of HIV-1 in plasma in late stages of the HIV infection (Ho et aI., 1989) would indicate that an early treatment of patients could be more effective than a late, due to a lower dose.
In view of the low frequency of infection after accidental exposure to HIV by needle sticks (Henderson and Gerberding, 1989) it could be assumed that the infectious dose in such cases is rather low. The lack of detectable viral antigen production and negative virus isolations in 2 out of 4 monkeys treated with FLT before inoculation with 2-10 MID so of SIV sM indicates that a study in monkeys starting treatment after virus inoculation should be worthwhile despite a case report on failure of early AZT treatment after accidental exposure to HIV (Lange et al., 1990) . In this case a high dose of virus and infected cells, 10D-200 J.LI blood from a late stage AIDS patient, was probably injected. The present results show the importance of the dose of SIV sM given to cynomolgus monkeys for the response to antiviral treatment with FLT. It seems likely that the effects of other anti-HIV drugs evaluated in SIV-infected monkeys will depend on the infectious dose of virus and that when evaluating antiviral drugs the multiplicity or infectious dose has to be considered both in vitro and in Vivo.
Materials and Experimental procedures
The methods and materials used have been described earlier (Lundgren et aI., 1990 (Lundgren et aI., , 1991 . The cynomolgus monkeys (Macaca fascicularis) were housed in single cages in a biosafety level 3 facility. FLT, obtained from Medivir AB, Huddinge, Sweden, was dissolved-in phosphate buffered saline and used at a dose level of 3 x 5 mg kg-1 day:". Treatment with FLT consisted of subcutaneous injections every 8h for 10day and started 8h before inoculation with SIV s M . The second treatment was given 10 min prior to virus inoculation. The half-life of FLT in monkeys is 55 ± 4 min when given l.v, (Lundgren et al., 1991) but the intracellular half-life of the active triphosphate has not been studied in vivo. Four monkeys in each treatment group were given intravenously one ml of SIVs M containing different amounts of virus. Appearance of SIV s M viral antigen in serum was measured by a HIV p24 antigen assay (Abbott Laboratories, North Chicago, IL, USA) and used as an efficacy parameter. SIV s M was kindly provided by Drs P. Fultz and H. McClure, Yerkes Primate Research Center, Animal Resources Branch, NIH, grant No. RR·00165. Two different pools of SIV s M were used. These had been prepared in PHA stimulated human lymphocytes. Reverse transcriptase (RT)activity was determined as described by Vrang et al. (1988) and the virus titre was determined by endpoint dilution assay in human lymphocytes and given as tissue culture infectious doses (TCID 50). The amount of infectious virus was titrated in cynomolgus monkeys as earlier described (Lundgren et al., 1990 (Lundgren et al., , 1991 . One ml of SIV pool I diluted 1/100 was shown to contain 10-100 monkey infectious doses (MID50), whereas SIV pool II had a higher virus content and at the same dilution 1 ml contained 500-2500 MID 5o.
Serum samples from the monkeys were collected on days 0, 4, 6, 8, 10, 14, 20, and for some animals also on day 30, and seronegative animals were further analysed by virus isolation and for seroconversion on days 60, 90, and 190. Serum samples from earlier control monkeys with SIV pool I and II and at doses of 2-50 MID 50 had been collected on days 0, 4, 6, 8, 10, 14, 17, and 22 . To be able to add the control monkeys in these experiments to the groups of previous controls with the same infectious dose of virus the average of p24/26 antigen values for days 17 and 22 were plotted as day 20. The serum samples were kept at -20°C until screened for viral antigen and antibodies.
A non-parametric statistical method was used (Wilcoxons Rank Sum, one-tailed) for the comparison of differences in the time from virus inoculation to viral antigen appearance, as described earlier (Lundgren et al., 1990 (Lundgren et al., , 1991 . P-values <:;0.05 were considered significant. A significant level of p24/26 was defined as an OD 4 9 2 reading of more than 0.04 when the mean background level at day 0 was subtracted.
